{"id":63010,"date":"2026-04-27T16:02:21","date_gmt":"2026-04-27T14:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/evofem-announces-exclusive-agreement-for-the-distribution-and-commercialization-of-solosec-in-sub-saharan-africa\/"},"modified":"2026-04-27T16:02:21","modified_gmt":"2026-04-27T14:02:21","slug":"evofem-announces-exclusive-agreement-for-the-distribution-and-commercialization-of-solosec-in-sub-saharan-africa","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/evofem-announces-exclusive-agreement-for-the-distribution-and-commercialization-of-solosec-in-sub-saharan-africa\/","title":{"rendered":"Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa"},"content":{"rendered":"
\n

\n\u2014 SOLOSEC\u00ae<\/sup> (secnidazole) 2g Oral Granules is an FDA-Approved <\/b><\/i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis \u2014<\/i><\/b><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–$EVFM<\/a> #BV<\/a>–Women\u2019s health innovator Evofem Biosciences, Inc.<\/a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC<\/a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC\u00ae<\/sup> (secnidazole) 2g oral granules<\/a> in sub-Saharan Africa (the Territory).<\/p>\n

<\/a>
<\/a><\/p>\n

\nSOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in females 12 years of age and older and to treat Trichomoniasis (Trich), a common sexually transmitted infection (STI), in people 12 years of age and older.<\/p>\n

\n\u201cWomen everywhere deserve access to effective drugs that treat common sexual health conditions with simple, patient-friendly dosing regimens. We are delighted that Clovis Davis will distribute SOLOSEC\u2014Evofem\u2019s single-dose oral treatment for BV and Trich\u2014in Africa, greatly increasing its global reach,\u201d said Saundra Pelletier, Chief Executive Officer of Evofem.<\/p>\n

\n\u201cWe believe SOLOSEC will be well received among healthcare providers and patients in our target markets because it delivers a complete treatment for BV and Trich with just one oral dose, enabling patients to quickly resume their normal, daily lives,\u201d said Jeff Reichman, Chief Operating Officer of Clovis Davis. \u201cIn parallel with SOLOSEC distribution, Clovis Davis is developing comprehensive women’s health initiatives in Ethiopia and Uganda beginning with the OSOM\u00ae<\/sup> BVBlue<\/a>\u00ae<\/sup> test, an FDA-cleared and CLIA-waived innovative point-of-care diagnostic test that enables rapid, accurate detection of bacterial vaginosis in clinical settings. This aligns with our commitment to not only treat, but also to improve early detection and diagnosis of BV in underserved markets where access to laboratory infrastructure may be limited.\u201d<\/p>\n

\nBV is estimated to affect 25% of women in sub-Saharan Africa1<\/sup>. In Ethiopia alone, of the 43.8 million women aged 12 years and older2<\/sup>, 10.9 million women may be eligible for treatment with SOLOSEC.<\/p>\n

\nTrichomoniasis is caused by the parasite Trichomonas vaginalis<\/i>; successful resolution of this common STI requires testing and a complete course of antibiotic treatment of all infected partners. Per the World Health Organization (WHO), there were an estimated 156 million new cases of Trichomoniasis among people aged 15\u201349 years old in 2020 (73.7 million in females and 82.6 million in males). Approximately one third of new infections in this age group occur in the WHO African Region.3<\/sup><\/p>\n

\nClovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory. Local regulatory filings for approval of SOLOSEC will be based on Evofem\u2019s registration dossier submitted and approved by the U.S. FDA.<\/p>\n

\nAbout Evofem Biosciences<\/b><\/p>\n

\nEvofem Biosciences, Inc.<\/a> is commercializing two FDA-approved sexual and reproductive health products:<\/p>\n